Full Text
PCN52 ECONOMIC ANALYSIS OF ERLOTINIB, DOCETAXEL, PEMETREXED AND BEST SUPPORTIVE CARE AS 2ND OR 3RD LINE TREATMENT OF NON-SMALL CELL LUNG CANCER

Abstract

Authors

F Negreiro C Pereira H Pereira C Silva

Back to Volume 11, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×